Positron emission tomography in neurological and psychiatric disorders

International Journal of Imaging Systems and Technology

Volumn 22, Issue 1, 2012, Pages 2-17

  Newberg, Andrew ^a   Monti, Daniel ^a   Moss, Aleeze ^a   Alavi, Abass ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

disorders; neurological; positron emission tomography; psychiatric

Indexed keywords

CLINICAL APPLICATION; CLINICAL SETTINGS; DIAGNOSTIC INFORMATION; DISORDERS; LARGE ARRAYS; NEUROLOGICAL; PATHOPHYSIOLOGY; PET IMAGING; POSITRON EMISSION; PSYCHIATRIC; PSYCHIATRIC DISORDERS;

NEUROPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY;

NEUROIMAGING;

EID: 84857225966     PISSN: 08999457     EISSN: 10981098     Source Type: Journal    
DOI: 10.1002/ima.22004     Document Type: Article

References (169)

1. R. Ackerman, J. Correia, N. Alpert, J.C. Baron, A. Gouliamos, J.C. Grotta, G.L. Brownell, and, T.M. Taveras, Positron imaging in ischemic stroke disease using compound labeled with oxygen-15. Arch Neurol 38 (1981), 537-543.
2. E. Akimova, R. Lanzenberger, and, S. Kasper, The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 66 (2009), 627-635.
3. A. Alavi, P.R. Jolles, and D. G. Jamieson, Anatomic and functional changes of the brain in normal aging and dementia as demonstrated by MRI, CT, and PET. Nucl Med Ann (1989), 49-79.
4. G.E. Alexander, K. Chen, P. Pietrini, S.I. Rapoport, and, E.M. Reiman, Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159 (2002), 738-745. (Pubitemid 34465046)
5. N.C. Andreasen, D.S. O'Leary, M. Flaum, P. Nopoulos, G.L. Watkins, L.L. Boles Ponto, and, R.D. Hichwa, Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349 (1997), 1730-1734. (Pubitemid 27252672)
6. R. Bakshi, R.S. Miletich, P.R. Kinkel, M.L. Emmet, and, W.R. Kinkel, High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 8 (1998), 228-234. (Pubitemid 28457989)
7. B. Ballanger, H. Klinger, J. Eche, J. Lerond, A.E. Vallet, D.D. Le Bars, L. Tremblay, V. Sgambato-Faure, E. Broussolle, and, S. Thobosis, Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord (2011) [Epub ahead of print].
8. J. Baron, M. Bousser, D. Comar, and, P. Castaigne, Crossed cerebellar diaschisis in human supratentorial brain infarction. Trans Am Neurol Assoc 105 (1980), 459-461.
9. J. Baron, M. Bousser, D. Comar, and, P. Castaigne, crossed cerebellar disaschisis in human supratentorial brain infarction, EurNeurol 20 (1981), pp. 273-284.
10. J. Baron, M. Bousser, A. Rey, A. Guillard, D. Comar and P. Castaigne, Reversal of focal "misery-perfusion syndrome" by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. Stroke 12 (1981b), 454-459. (Pubitemid 11046690)
11. J. Baron, M.G. Bousser, and, D. Comar, Crossed cerebellar diaschisis: A remote functional depression secondary to supratentorial infarction in man. J Cerebr Blood Flow Metab 1 (1981c), S500-S501.
12. J. Baron, R. Frackowiak, K. Herholz, T. Jones, A.A. Lammertsma, B. Mazoyer and K. Wienhard, Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease. J Cerebr Blood Flow Metab 9 (1989), 723-742. (Pubitemid 20006891)
13. L. Baxter, M. Phelps, J. Mazziotta, B.H. Guze, J.M. Schwartz, and, C.E. Selin, Local cerebral glucose metabolic rates in obsessive-compulsive disorder: A comparison with rates in unipolar depression and normal controls. Arch Gen Psychiatr 44 (1987), 211-218. (Pubitemid 17023134)
14. L. Baxter, J. Schwartz, J. Mazziotta, M.E. Phelps, J.J. Pahl, B.H. Guze, and, L. Fairbanks, Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 145 (1988), 1560-1563. (Pubitemid 19009706)
15. D. Ben-Shachar, O. Bonne, R. Chisin, E. Klein, H. Lester, J. Aharon-Peretz, I. Yona, and, N. Freedman, Cerebral glucose utilization and platelet mitochondrial complex l activity in schizophrenia: A FDG-PET study. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007), 807-813. (Pubitemid 46671478)
16. F. Biver, D. Wikler, F. Lotstra, P. Damhaut, S. Goldman, and, J. Mendlewicz, Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Brit J Psychiatr 171 (1997), 444-448. (Pubitemid 27475842)
17. R. Blesa, J. Blin, et al., Levodopa-reduced glucose metabolism in striatopallidothalamocortico circuit in Parkinson's disease. Neurology 41 (1991), 359.
18. M. Blinkenberg, K. Rune, C.V. Jensen, M. Ravnborg, S. Kyllingsbaek, S. Holm, O.B. Paulson, and, P.S. Sørensen, Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 54 (2000), 558-564. (Pubitemid 30082918)
19. 11C]DASB. Mov Disord 12 (2008), 1776-1780.
20. A.L. Brody, S. Saxena, J.M. Schwartz, P.W. Stoessel, K. Maidment, M.E. Phelps, and, L.R. Baxter Jr, FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatr Res 84 (1998), 1-6. (Pubitemid 28546878)
21. A.L. Brody, S. Saxena, D.H. Silverman, S. Alborzian, L.A. Fairbanks, M.E. Phelps, S.C. Huang, H.M. Wu, K. Maidment, and, L.R. Baxter Jr, Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatr Res 91 (1999), 127-139. (Pubitemid 29474048)
22. K. Broich, A. Alavi, and, M. Kushner, Positron emission tomography in cerebrovascular disorders. Semin Nucl Med 22 (1992), 224-232.
23. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28 (1990), 547-555. (Pubitemid 20359162)
24. 18F]fluoro- L -dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 26 (2005), 891-898. (Pubitemid 40249492)
25. M.S. Buchsbaum, and, E.A. Hazlett, Positron emission tomography studies of abnormal glucose metabolism in schizophrenia, Schizophr Bull 24 (1998) pp. 343-64. (Pubitemid 28378221)
26. M. S. Buchsbaum, B. T. Christian, D. S. Lehrer, T. K. Narayanan, B. Shi, J. Mantil, E. Kemether, T. R. Oakes, and, J. Mukherjee, D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia, Schizophr Res 85 (2006), pp. 232-244 [Epub 2006 May 19]. (Pubitemid 43947535)
27. M.S. Buchsbaum, J. Wu, R. Haier, E. Hazlett, R. Ball, M. Katz, K. Sokolski, M. Lagunas-Solar, and, D. Langer, Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder. Life Sci 40 (1987), 2393-2400. (Pubitemid 17083949)
28. A.R. Childress, P.D. Mozley, W. McElgin, J. Fitzgerald, M. Reivich, and, C.P. O'Brien, Limbic activation during cue-induced cocaine craving. Amer J Psychiatr 156 (1999), 11-18. (Pubitemid 29034874)
29. C. Clark, L. Kopala, D.K. Li, and, T. Hurwitz, Regional cerebral glucose metabolism in never-medicated patients with schizophrenia. Can J Psychiatry 46 (2001), 340-346.
30. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, M.J. Pontecorvo, F. Hefti, A.P. Carpenter, M.L. Flitter, M.J. Krautkramer, H.F. Kung, R.E. Coleman, P.M. Doraiswamy, A.S. Fleisher, M.N. Sabbagh, C.H. Sadowsky, E.P. Reiman, S.P. Zehntner, and D.M. Skovronsky, AV45-A07 Study Group, Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305 (2011), 275-283.
31. R.M. Cohen, P.J Andreason, and, T. Sunderland, The ratio of mesial to neocortical temporal lobe blood flow as a predictor of dementia. J Am Geriatr Soc 45 (1997), 329-333. (Pubitemid 27114306)
32. 18F]FDOPA. Psychiatry Res 163 (2008), 171-182.
33. M.H. Dao-Castellana, M.L. Paillère-Mártinot, P. Hantraye, D. Attar-Lévy, P. Rémy,. Presynaptic dopamine function in the striatum of schizophrenic patients, Schizophr Res 23 (1997), 167-174. (Pubitemid 27106901)
34. 11C]PK11195. Eur J Neurol 10 (2003), 257-264. (Pubitemid 36609480)
35. S. Dethy, N. Van Blercom, P. Damhaut, D. Wikler, J. Hildebrand, and, S. Goldman, Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism. Mov Disord 13 (1998), 275-280. (Pubitemid 28127803)
36. J. Diehl, T. Grimmer, A. Drzezga, M. Riemenschneider, H. Förstl, and, A. Kurz, Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia, a PET study. Neurobiol Aging 25 (2004), 1051-1056. (Pubitemid 38798067)
37. W.C. Drevets, E. Frank, J.C. Price, D.J. Kupfer, P.J. Greer, and, C. Mathis, Serotonin type-1A receptor imaging in depression. Nucl Med Biol 27 (2000), 499-507. (Pubitemid 30658154)
38. W.C. Drevets, J.L. Price, J.R. Simpson, R.D. Todd, T. Reich, M. Vannier, and, M.E. Raichle, Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386 (1997), 824-827. (Pubitemid 27181254)
39. W.C. Drevets, M.E. Thase, E.L Moses-Kolko, J. Price, E. Frank, D.J. Kupfer, and, C. Mathis, Serotonin-1A receptor imaging in recurrent depression: Replication and literature review. Nucl Med Biol 34 (2007), 865-877. (Pubitemid 47505401)
40. R. Duara, C. Grady, J. Haxby, M. Sundaram, N.R. Cutler, L. Heston, A. Moore, N. Schlageter, S. Larson, and, S.I. Rapoport, Positron emission tomography in Alzheimer's disease. Neurology 36 (1986), 879-887. (Pubitemid 16098229)
41. T.S. Early, E.M. Reiman, M.E. Raichle, and, E.L. Spitznagel, Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc Natl Acad Sci USA 84 (1987), 561-563. (Pubitemid 17006235)
42. 18F) fluorodopa positron emission tomographic studies. Move Dis 5 (1990), 203-213. (Pubitemid 20311769)
43. A.M. Elkashet, D. Doudet, T. Bryant, R.M. Cohen, S.H. Li, and, R.J. Wyatt, 6-(18)F-DOPA PET study in patients with schizophrenia. Psychiatry Res 100 (2000), 1-11.
44. M. Franceschi, D. Anchisi, O. Pelati, M. Zuffi, M. Matarrese, R.M. Moresco, F. Fazio, and, D. Perani, Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 57 (2005), 216-225. (Pubitemid 40179860)
45. T. Fujimoto, K. Takeuch, T. Matsumoto, K. Kamimura, R. Hamada, K. Nakamura, and, N. Kato, Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia. Psychiatry Res 154 (2007), 49-58. (Pubitemid 46072705)
46. S. Gilman, K. Adams, R.A. Koeppe, S. Berent, K.J. Kluin, J.G. Modell, P. Kroll, and, J.A. Brunberg, Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography. Ann Neurol 28 (1990), 775-785.
47. S. Gilman, K.M. Adams, D. Johnson-Greene, R.A. Koeppe, L. Junck, K.J. Kluin, S. Martorello, M. Heumann, and, E. Hill, Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. Alcohol Clin Exp Res 20 (1996), 1456-1461. (Pubitemid 26393950)
48. 11C]dihydrotetrabenazine and positron emission tomography. Ann Neurol 44 (1998), 326-333. (Pubitemid 28421436)
49. 18F-FDG-PET study. Dem Geriatric Cog Dis 18 (2004), 32-36. (Pubitemid 38822735)
50. R.E. Gur, R.C. Gur, B.E. Skolnick, S. Caroff, W.D. Obrist, S. Resnick, and, M. Reivich, Brain function in psychiatric disorders III. Regional cerebral blood flow in unmedicated schizophrenics. Arch Gen Psychiatry 42 (1985), 329-334. (Pubitemid 15018300)
51. J.C. Haxby, R. Duara, C.L. Grady, N.R. Cutler, and, S.I. Rapoport, Relationship between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cerebr Blood Flow Metab 5 (1985), 193-200. (Pubitemid 15123204)
52. W.D. Heiss, and, R. Hilker, The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 11 (2004), 5-12; Review. (Pubitemid 38174915)
53. W.D. Heiss, G. Pawlik, K. Herholz, B. Szelies, and, K. Wienhard, Positron emission tomography as an imaging tool in psychiatric disorders. Psychiatry Res 29 (1989), 351-352. (Pubitemid 19265389)
54. K. Herholz, W. Heindel, A. Rackl, I. Neubauer, W. Steinbrich, U. Pietrzyk, H. Erasmi-Körber, and, W.D. Heiss, Regional cerebral blood flow in leukoaraiosis and artherosclerotic carotid disease. Arch Neurol 47 (1990), 392-397.
55. K. Herholz, and, W. Heiss, "Use of PET to evaluate acute stroke and other cerebrovascular disorders," In Radiopharmaceuticals and brain pathology studies with PET and SPECT, M.M. Diksic, and, R. Reba, (Editors), CRC, Boca Raton, 1991, pp. 217-239.
56. J. Hietala, E. Syvalahti, H. Vilkman, K. Vuorio, V. Räkkö läinen, J. Bergman, M. Haaparanta, O. Solin, M. Kuoppamäki, E. Eronen, U. Ruotsalainen, and, R.K. Salokangas, Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schiz Res 35 (1999), 41-50. (Pubitemid 29023553)
57. K. Hill, L. Mann, K.R. Laws, C.M. Stephenson, I. Nimmo-Smith, and, P.J. McKenna, Hypofrontality in schizophrenia: A meta-analysis of functional imaging studies. Acta Psychiatr Scand 110 (2004), 243-256. (Pubitemid 39278982)
58. N. Hirono, E. Mori, M. Yasuda, K. Ishii, Y. Ikejiri, T. Imamura, T. Shimomura, M. Hashimoto, H. Yamashita, and M. Sasaki, Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis Assoc Disord 12 (1998), 362-367. (Pubitemid 29050752)
59. A.P. Ho, J.C. Gillin, M.S. Buchsbaum, J.C. Wu, L. Abel, and, W.E. Bunney Jr, Brain glucose metabolism during non-rapid eye movement sleep in major depression, a positron emission tomography study. Arch Gen Psychiatry 53 (1996), 645-652. (Pubitemid 26240867)
60. D. Hommer, P. Andreasen, D. Rio, W. Williams, U. Ruttimann, R. Momenan, A. Zametkin, R. Rawlings, and, M. Linnoila, Effects of m-chlorophenylpiperazine on regional brain glucose utilization: A positron emission tomographic comparison of alcoholic and control subjects. J Neurosci 17 (1997), 2796-2806. (Pubitemid 27155013)
61. O.D. Howes, A.J. Montgomery, M.C. Asselin, R.M. Murray, I. Valli, P. Tabraham, E. Bramon-Bosch, L. Valmaggia, L. Johns, M. Broome, P.K. McGuire, and, P.M. Grasby, Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66 (2009), 13-20.
62. A. Hunt, P. Schonknect, M. Henze, U. Seidl, U. Haberkorn, and, J. Schröder, Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res 155 (2007), 147-154. (Pubitemid 46874914)
63. V. Ibáñezs, P. Pietrini, G.E. Alexander, M.L. Furey, D. Teichberg, J.C. Rajapakse, S.I. Rapoport, M.B. Schapiro, and, B. Horwitz, Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50 (1998), 1585-1593. (Pubitemid 28283222)
64. S. Iglesias, G. Marchal, F. Viader, and, J.C. Baron, Delayed intrahemispheric remote hypometabolism. Correlations with early recovery after stroke. Cerebrovasc Dis 10 (2000), 391-402.
65. T.R. Insel and J.T. Winslow, Neurobiology of obsessive-compulsive disorder. Psychiatr Clin N Am 15 (1992), 813-824.
66. K. Ishii, S. Sakamoto, M. Sasaki, H. Kitagaki, S. Yamaji, M. Hashimoto, T. Imamura, T. Shimomura, N. Hirono, and, E. Mori, Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 39 (1998), 1875-1878. (Pubitemid 28518885)
67. 18F]fluoro- L -dopa PET study. Brain 25 (2002), 1358-1365. (Pubitemid 34587144)
68. W.J. Jagust, R.P. Friedland, T.F. Budinger, E. Koss, and, B. Ober, Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 38 (1988), 909-912.
69. V. Jelic and A. Nordberg, Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord 14 (2000), S109-S113.
70. I.H. Jenkins, W. Fernandez, E.D. Playford, A.J. Lees, R.S. Frackowiak, R.E. Passingham, and, D.J. Brooks, Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32 (1992), 749-757.
71. V. Kaasinen and J.O. Rinne, Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev 26 (2002), 785-793.
72. V. Kaasinen, E. Nurmi, A. Brück, et al., Increased frontal [18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex, Brain 124 (2001), 1125-1130. (Pubitemid 32510380)
73. N. Kemppainen, M. Laine, M.P. Laakso, V. Kaasinen, K. Någren, T. Vahlberg, T. Kurki, and, J.O. Rinne, Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 19 (2003), 149-154. (Pubitemid 36920856)
74. A.M. Kennedy, M.N. Rossor, and, R.S. Frackowiak, Positron emission tomography in familial Alzheimer disease. Alzheimer Dis Assoc Disord 9 (1995), 17-20.
75. S. Kern, T.R. Oakes, C.K. Stone, E.M. McAuliff, C. Kirschbaum, and, R.J. Davidson, Glucose metabolic changes in the prefrontal cortex are associated with HPA axis response to a psychosocial stressor. Psychoneuroendocrinology 33 (2008), 517-529.
76. T.W. Kjaer, C. Bertelsen, P. Piccini, D. Brooks, J. Alving, and, H.C. Lou, Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res 13 (2002), 255-259. (Pubitemid 34212051)
77. 11C]flumazenil binding in major depression: Preliminary results. J Nucl Med Mol Imaging 37 (2010), 565-574.
78. W. Klunk, C. Mathis, Y. Wang, Y. Huang, D. Holt, M. Debnath, H. Engler, A. Nordberg, G. Blomqvist, M. Bergström, S. Estrada, J. Barletta, J. Sandell, G. Antoni, and, B. Långström, Binding of a benzothiazole amyloid-imaging PET tracer to human brain is dominated by specific interaction with the amyloid component in vitro and in vivo, 32nd Annual Meeting of Society for Neuroscience, Orlando, FL, 2002.
79. D.E. Kuhl, E.J. Metter, D. F. Benson, J.W. Ashford, W.H. Riege, D.G. Fujikawa, C.H. Marham, and, A. Maltese, Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia [Abstract]. J Nucl Med 26 (1985), P69.
80. 18FDG and 12NH3. Ann Neurol 8 (1980), 47-69.
81. A. Kumar, A. Newberg, A. Alavi, J. Berlin, R. Smith, and, M. Reivich, Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: A preliminary positron emission tomography study. Proc Natl Acad Sci USA 90 (1993), 7019-7023. (Pubitemid 23222380)
82. M. Kushner, A. Alavi, M. Reivich, R. Dann, A. Burke, and, G. Robinson, Contralateral cerebellar hypometabolism following cerebral insult: A positron emission tomographics study. Ann Neurol 15 (1984), 425-434. (Pubitemid 14145567)
83. M. Kushner, C. Fieschi, and, M. Reivich, "Focal and remote dysmetabolism in stroke," In Cerebral ischemia and hemorology, A. Hartmann, and, W. Kuschinsky, (Editors), Springer-Verlag, Berlin, 1987a.
84. M. Kushner, M. Reivich, C. Fieschi, F. Silver, J. Chawluk, M. Rosen, J. Greenberg, A. Burke, and, A. Alavi, Metabolic and clinical correlates of acute ischemic infarction. Neurology 37 (1987b), 1103-1110. (Pubitemid 17123440)
85. C. Labbe, J.C. Froment, A. Kennedy, J. Ashburner, and, L. Cinotti, Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging. Alzheimer Dis Assoc Disord 10 (1996), 141-170. (Pubitemid 26306100)
86. K.L. Lanctot, N. Herrmann, H. Ganjavi, S.E. Black, P.M. Rusjan, S. Houle, and, A.A. Wilson, Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res 156 (2007), 247-250. (Pubitemid 350116557)
87. N. Lassen, The luxury perfusion syndrome and its possible relation to acute metabolic acidosis localized within the brain. Lancet 2 (1966), 1113-1115.
88. K.L. Leenders, A.J. Palmer, N. Quinn, J.C. Clark, G. Firnau, E.S. Garnett, C. Nahmias, T. Jones, and, C.D. Marsden, Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49 (1986), 853-860. (Pubitemid 16048411)
89. G. Lenzi, R. Frackowiak, and, T. Jonres, Cerebral oxygen metabolism and blood flow in human cerebral ischemic infarction. J Cerebr Blood Flow Metab 2 (1982), 321-335. (Pubitemid 12015758)
90. 11C) DOPA and PET. Biol Psychiatry 46 (1999), 681-688. (Pubitemid 29401864)
91. E.D. London, N.G. Cascella, D.F. Wong, R.L. Phillips, R.F. Dannals, J.M. Links, R. Herning, R. Grayson, J.H. Jaffe, and, H.N. Wagner Jr, Cocaine-induced reduction of glucose utilization in human brain: A study using positron emission tomography and (fluorine-18)-fluorodeoxyglucose. Arch Gen Psychiatr 47 (1990), 567-574. (Pubitemid 20189969)
92. G. Marchal, A. Evans, A. Dagher, The evolution of cerebral infarction with time: A PET study of the ischemia penumbra. J Cerebr Blood Flow Metab 7 (1987), S99.
93. 18F]altanserin-PET study. Neurobiol Aging (2010) [Epub ahead of print].
94. L. Marner, G.M. Knudsen, K. Madsen, S. Holm, W. Baaré, and, S.G. Hasselbalch, The reduction of baseline serotonin 2A receptors in mild cognitive impairment is stable at two-year follow-up. J Alzheimers Dis 23 (2011), 453-459.
95. D. Martinez, A. Broft, R.W. Foltin, M. Slifstein, D.R. Hwang, Y. Huang, A. Perez, W.G. Frankle, T. Cooper, H.D. Kleber, M.W. Fischman, and, M. Laruelle, Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: Relationship with cocaine-seeking behavior. Neuropsychopharmacology 29 (2004), 1190-1202. (Pubitemid 38670055)
96. D. Martinez, M. Slifstein, R. Narendran, R.W. Foltin, A. Broft, D.R. Hwang, A. Perez, A. Abi-Dargham, M.W. Fischman, H.D. Kleber, and, M. Laruelle, Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology 34 (2009), 1774-1782.
97. M. Martinot, V. Bragulat, E. Artiges, F. Dollé, F. Hinnen, R. Jouvent, and, J. Martinot, Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Amer J Psychiatr 158 (2001), 314-316. (Pubitemid 32116533)
98. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46 (2003), 2740-2754. (Pubitemid 36702542)
99. 11C]DASB PET study. Neuroimage 49 (2010), 121-126.
100. H.S. Mayberg, S.K. Brannan, J.L. Tekell, J.A. Silva, R.K. Mahurin, S. McGinnis, and, P.A. Jerabek, Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biol Psychiatr 48 (2000), 830-843.
101. J.C. Mazziotta, "Movement disorders," In Clinical brain imaging: Principles and applications, J.C. Maziotta, and, S. Gilman, (Editors), Davis, Philadelphia, 1992, pp. 244-293.
102. C.C. Meltzer, J.C. Price, C.A. Mathis, P.J. Greer, M.N. Cantwell, P.R. Houck, B.H. Mulsant, D. Ben-Eliezer, B. Lopresti, S.T. DeKosky, and, C.F. Reynolds 3rd, PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Amer J Psychiatr 156 (1999), 1871-1878.
103. J.H. Meyer, Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32 (2007), 86-102. (Pubitemid 46597955)
104. J.H. Meyer, S. Kapur, B. Eisfeld, G.M. Brown, S. Houle, J. DaSilva, A.A. Wilson, S. Rafi-Tari, H.S. Mayberg, and, S.H. Kennedy, The effect of paroxetine on 5-HT(2A) receptors in depression: An [(18)F]setoperone PET imaging study. Amer J Psychiatr 158 (2001), 78-85. (Pubitemid 32047250)
105. J.G. Modell, J.M. Mountz, G. Curtis, and, J.F. Greden, Neurophysiologic dysfunctions in basal ganglia limbic striatal and thalamorcortical circuit as a pathogenetic mechanism of obsessive compulsive disorder. J Neuropsychiatry 1 (1989), 27-36. (Pubitemid 19247050)
106. R.M. Moresco, L. Pietra, M. Henin, A. Panzacchi, M. Locatelli, L. Bonaldi, A. Carpinelli, C. Gobbo, L. Bellodi, D. Perani, and, F. Fazio, Fluvoxamine treatment and D2 receptors: A pet study on OCD drug-naïve patients. Neuropsychopharmacology 32 (2007), 197-205. (Pubitemid 44967798)
107. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59 (1995), 597-600.
108. A. Newberg, A. Alavi and C. Clark, The metabolic imaging severity rating scale (MISRS) in Alzheimer's disease: Comparison with quantitative data. Eur J Nuclear Med 25 (1998), 1068.
109. M. Nishikawa, M. Diksic, Y. Sakai, H. Kumano, D. Charney, J. Palacios-Boix, J. Negrete, and, K. Gill, Alterations in brain serotonin synthesis in male alcoholics measured using positron emission tomography. Alcohol Clin Exp Res 33 (2009), 233-239.
110. T.E. Nordahl, C. Benkelfat, W. Semple, M. Gross, A.C. King, and, R.M. Cohen, Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 2 (1989), 23-28. (Pubitemid 19126156)
111. R.A. O'Connell, R.L Van RL, and, A.R. Holt, Single photon emission computed tomography in psychiatry. Clin Nucl Med 12 (1987), 13.
112. Y. Okubo, T. Suhara, K. Suzuki, K. Kobayashi, O. Inoue, O. Terasaki, Y. Someya, T. Sassa, Y. Sudo, E. Matsushima, M. Iyo, Y. Tateno, and, M. Toru, Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 (1997), 634-636.
113. M. Ono, M.P. Kung, C. Hou and H.F. Kung, Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol 29 (2002), 633-642. (Pubitemid 35266662)
114. P. Pantano, J. Baron, Y. Samson, M.G. Bousser, C. Derouesne, and, D. Comar, Crossed cerebellar diaschisis, further studies. Brain 109 (1986), 634-677.
115. K.M. Park, J.J. Kim and J.H. Seok, Anhedonia and ambivalence in schizophrenia patients with fronto-cerebellar metabolic abnormalities: A fluoro-d-glucose positron emission tomography study. Psychiatry Investig 6 (2009), 72-77.
116. 18F] FDG PET study. Neuroimage 4 (1996), 87-96. (Pubitemid 26337401)
117. G.D. Pearlson, D.F. Wong, L.E. Tune, C.A. Ross, G.A. Chase, J.M. Links, R.F. Dannals, A.A. Wilson, H.T. Ravert, and, H.N. Wagner Jr, In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatr 52 (1995), 471-477.
118. R.F. Peppard, W.R. Martin, C.M. Clark, G.D. Carr, P.L. McGeer, and, D.B. Calne, Cortical glucose metabolism in Parkinson's and Alzheimer's disease. J Neurosci Res 27 (1990), 561-568.
119. D. Perani, V. Garibotto, A. Gorini, R.M. Moresco, M. Henin, A. Panzacchi, M. Matarrese, A. Carpinelli, L. Bellodi, and, F. Fazio, In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 42 (2008), 306-314.
120. M.E. Phelps, J.C. Mazziotta, L. Baxter, and, R. Gerner, Positron emission tomographic study of affective disorders, problems and strategies. Ann Neurol 15 (1984), S149-S156. (Pubitemid 14138677)
121. 11C-DASB PET study. Neurobiol Dis 40 (2010), 216-221.
122. C. Pozzilli, D. Passafiume, A. Anzini, G. Borsellino, T. Koudriavsteva, G. Sarlo, and, C. Fieschi, Cognitive and brain imaging measures of multiple sclerosis. Ital J Neurol Sci 13 (1992), 133-136; Review.
123. J.C. Pruessner, K. Dedovic, M. Pruessner, C. Lord, C. Buss, L. Collins, A. Dagher, and, S.J. Lupien, Stress regulation in the central nervous system: Evidence from structural and functional neuroimaging studies in human populations-2008 Curt Richter Award Winner. Psychoneuroendocrinology 35 (2010), 179-191.
124. 18F]dopa-PET study. Brain 122 (1999), 1637-1650. (Pubitemid 29425668)
125. E. Reiman, M. Rachle, F. Butler, P. Herscovitch, and, E. Robins, A focal brain abnormality in panic disorder: A severe form of anxiety. Nature 310 (1984), 683-685. (Pubitemid 14054331)
126. E. Reiman, M. Rachle, E. Robbins, M.A. Mintun, M.J. Fusselman, P.T/ Fox, J.L. Price, and, K.A. Hackman, Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatr 46 (1989), 493-500. (Pubitemid 19153875)
127. E.M. Reiman, R.J. Caselli, L.S. Yun, K. Chen, D. Bandy, S. Minoshima, S.N. Thibodeau, and, D. Osborne, Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Eng J Med 334 (1996), 752-758. (Pubitemid 26089356)
128. J. Reith, C. Benkelfat, A. Sherwin, Y. Yasuhara, H. Kuwabara, F. Andermann, S. Bachneff, P. Cumming, M. Diksic, S.E. Dyve, P. Etienne, A.C. Evans, S. Lal, M. Shevell, G. Savard, D.F. Wong, G. Chouinard, and, A. Gjedde, Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91 (1994), 11651-11654. (Pubitemid 24356402)
129. 18F-fluorodeoxyglucose βpositron emission tomography study. Neurology 48 (1997), 1566-1571.
130. D. Rougemont, J.C. Baron, P. Collard, P. Bustany, D. Comar, and, Y. Agid, Local cerebral glucose utilization in treated and untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 47 (1984), 824-830. (Pubitemid 14059374)
131. H. Sach, J.A. Russel, and, D.R. Christman, Alteration of regional cerebral glucose metabolic rate in non-Korsakoff chronic alcoholism. Arch Neurol 44 (1987), 1242-1251. (Pubitemid 18004934)
132. 11C]WAY 100635. Int J Neuropsychopharmacol 13 (2010a), 785-791.
133. T. Saijo, A. Takano, T. Suhara, R. Arakawa, M. Okumura, T. Ichimiya, H.
134. Y. Samson, J.C. Baron, A. Feline, J. Bories, and, C. Crouzel, Local cerebral glucose utilization in chronic alcoholics, a positron tomography study. J Neurol Neurosurg Psychiatr 49 (1986), 1165-1170. (Pubitemid 16028700)
135. 11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatr 57 (2000), 174-180. (Pubitemid 30075269)
136. G.V. Sawle, N.F. Hymas, A.J. Lees, and, R.S. Frackowiak, Obsessional slowness. Functional studies with positron emission tomography. Brain 114 (1991), 2191-2202.
137. 18F]dopa positron emission tomography studies in an Irish kindred. Ann Neurol 32 (1992), 609-617.
138. S. Saxena, A.L. Brody, K.M. Maidment, J.J. Dunkin, M. Colgan, S. Alborzian, M.E. Phelps, and, L.R. Baxter Jr, Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21 (1999), 683-693.
139. 11C] raclopride at dopamine receptors in human subjects. Am J Psychiatr 154 (1997), 1209-1213. (Pubitemid 27369170)
140. J.M. Schwartz, P.W. Stoessel, L.R. Baxter, K.M. Martin, and, M.E. Phelps, Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatr 53 (1996), 109-113. (Pubitemid 26049387)
141. S. Selvaraj, M.N. Venkatesha, Z. Bhagwagar, S.K. Bose, R. Hinz, P.M. Grasby, and, P.J. Cowen, Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [(11)C]DASB. Psychopharmacology (Berl) 213 (2011), 555-562.
142. K. Shoghi-Jadid, G.W. GW, E.D. Agdeppa, V. Kepe, L.M. Ercoli, P. Siddarth, S. Read, N. Satyamurthy, A. Petric, S.C. Huang, and, J.R. Barrio, Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease: Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer disease. Am J Geriatr Psychiatry 10 (2002), 24-35.
143. G.S. Smith, M.J. de Leon, A.E. George, A. Kluger, N.D. Volkow, T. McRae, J. Golomb, S.H. Ferris, B. Reisberg, and, J. Ciaravino, Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: Pathophysiological implications. Arch Neurol 49 (1992), 1142-1150.
144. G.S. Smith, C.F. Reynolds, B. Pollock, S. Derbyshire, E. Nofzinger, M.A. Dew, P.R. Houck, D. Milko, C.C. Meltzer, and, D.J. Kupfer, Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatr 156 (1999), 683-689. (Pubitemid 29220064)
145. M. Soyka, W. Kock, H.J. Moller, T. Rüther, and, K. Tatsch, Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients: Results from a FDG-PET study. Eur Arch Psychiatry Clin Neurosci 255 (2005), 308-312. (Pubitemid 41618802)
146. T.L. Strickland, B.L. Miller, A. Kowell, and, R. Stein, Neurobiology of cocaine-induced organic brain impairment: Contributions from functional neuroimaging. Neuropsychol Rev 8 (1998), 1-9. (Pubitemid 28223312)
147. T. Suhara, Y. Okubo, F. Yasuno, Y. Sudo, M. Inoue, T. Ichimiya, Y. Nakashima, K. Nakayama, S. Tanada, K. Suzuki, C. Halldin, and, L. Farde, Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59 (2002), 25-30. (Pubitemid 34044401)
148. X. Sun, M. Tanaka, S. Kondo, K. Okamoto, and, S. Hirai, Clinical significance of reduced cerebral metabolism in multiple sclerosis: A combined PET and MRI study. Ann Nucl Med 12 (1998), 89-94. (Pubitemid 28259387)
149. S.E. Swedo, M.B. Schapiro, C.L. Grady, D.L. Cheslow, H.L. Leonard, A. Kumar, R. Friedland, S.I. Rapoport, and, J.L. Rapoport, Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatr 46 (1989), 518-523. (Pubitemid 19153879)
150. 11C]FLB 457. Int J Neuropsychopharmacol 6 (2003), 361-370. (Pubitemid 38146254)
151. J. Tiihonen, H. Vilkman, P. Rasanen, O.P. Ryynänen, H. Hakko, J. Bergman, T. Hämäläinen, A. Laakso, M. Haaparanta-Solin, O. Solin, M. Kuoppamäki, E. Syvälahti, and, J. Hietala, Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. Mol Psychiatr 3 (1998), 156-161. (Pubitemid 28149557)
152. N.D. Volkow, J.S. Fowler, A.P. Wolf, R. Hitzemann, S. Dewey, B. Bendriem, R. Alpert, and, A. Hoff, changes in brain glucose metabolism in cocaine dependence and withdrawal, Am J Psychiatr 148 (1991), pp. 621-626.
153. N.D. Volkow, and, J.S. Fowler, neuropsychiatric disorders: investigation of schizophrenia and substance abuse, SeminNucl Med 22 (1992), pp. 254- 267.
154. N.D. Volkow, R. Hitzemann, G.J. Wang, J.S. Fowler, A.P. Wolf, S.L. Dewey, L. Handlesman, Long-term frontal brain metabolic changes in cocaine abusers. Synapse 11 (1992), 184-190.
155. N.D. Volkow, G.J. Wang, J.S. Fowler, R. Hitzemann, S.J. Gatley, S.S. Dewey, and, N. Pappas, enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study, Amer J Psychiatr 155 (1998), pp. 200- 206. (Pubitemid 28074281)
156. N.D. Volkow, G.J. Wang, H. Begleiter, R. Hitzemann, N. Pappas, G. Burr, K. Pascani, C. Wong, J.S. Fowler, and, A.P. Wolf, regional brain metabolic response to lorazepam in subjects at risk for alcoholism, Alcoholism: Clin Experimen Res 19 (1995), pp. 510-516.
157. N.D. Volkow, G.J. Wang, M.W. Fischman, R. Foltin, J.S. Fowler, D. Franceschi, M. Franceschi, J. Logan, S.J. Gatley, C. Wong, Y.S. Ding, R. Hitzemann, N. Pappas, effects of route of administration on cocaine induced dopamine transporter blockade in the human brain, Life Sci 67 (2000), pp. 1507-1515. (Pubitemid 30658707)
158. N.D. Volkow, G.J. Wang, J.S. Fowler, J. Logan, S.J. Gatley, R. Hitzemann, A.D. Chen, S.L. Dewey, and, N. Pappas, decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects, Nature 386 (1997), pp. 830-833. (Pubitemid 27181256)
159. N.D. Volkow, G.J. Wang, R. Hitzemann, J.S. Fowler, A.P. Wolf, N. Pappas, A. Biegon, S.L. Dewey, Decreased cerebral response to inhibitory neurotransmission in alcoholics. Amer J Psychiatr 150 (1993), 417-422. (Pubitemid 23072466)
160. E. Vowinckel, D. Reutens, B. Becher, G. Verge, A. Evans, T. Owens, J.P. Antel, PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 50 (1997), 245-253.
161. G.J. Wang, N.D. Volkow, J.S. Fowler, P. Cervany, R.J. Hitzemann, N.R. Pappas, C.T. Wong, C. Felder, Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci 64 (1999), 775-784. (Pubitemid 29098972)
162. 11C-glucose. Acta Psychiatr Scand 78 (1988), 234-241.
163. J Wu, M.S. Buchsbaum, J.C. Gillin, C. Tang, S. Cadwell, M. Wiegand, A. Najafi, E. Klein, K. Hazen, W.E. Bunney, J.H. Fallon, and, D. Keator, Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Amer J Psychiatr 156 (1999), 1149-1158. (Pubitemid 29374872)
164. J.C. Wu, M.S. Buchsbaum, T.G. Hershey, E. Hazlett, N. Sicotte, and, J.C. Johnson, PET in generalized anxiety disorder. Biol Psychiatr 29 (1991), 1181-1199.
165. F. Yasuno, T. Suhara, Y. Ichimiya, A. Takano, T. Ando, and, Y. Okubo, Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55 (2004), 439-444. (Pubitemid 38338529)
166. L.N. Yatham, P.F. Liddle, J. Dennie, I.S. Shiah, M.J. Adam, C.J. Lane, R.W. Lam, and, T.J. Ruth, Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatr 56 (1999), 705-711. (Pubitemid 29357731)
167. L.N. Yatham, P.F. Liddle, I.S. Shiah, G. Scarrow, R.W. Lam, M.J. Adam, A.P. Zis, and, T.J. Ruth T, Brain serotonin receptors in major depression: A positron emission tomography study. Arch Gen Psychiatry 57 (2000), 850-858.
168. R. Zahn, J. Moll, V. Iyengar, E.D. Huey, M. Tierney, F. Krueger, and, J. Grafman, Social conceptual impairments in frontotemporal lobar degeneration with right anterior temporal hypometabolism. Brain 132 (2009), 604-616.
169. R. Zanardi, F. Artigas, R. Moresco, C. Colombo, C. Messa, C. Gobbo, E. Smeraldi, and, F. Fazio,. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: A positron emission tomography scan study. J Clin Psychiatropharmacol 21 (2001), 53-58. (Pubitemid 32096750)